nodes	percent_of_prediction	percent_of_DWPC	metapath
Lamivudine—ABCC3—Vincristine—muscle cancer	0.0657	0.0849	CbGbCtD
Lamivudine—ABCC1—Dactinomycin—muscle cancer	0.0655	0.0847	CbGbCtD
Lamivudine—SLC22A3—Vincristine—muscle cancer	0.0618	0.0798	CbGbCtD
Lamivudine—ABCC3—Etoposide—muscle cancer	0.0602	0.0778	CbGbCtD
Lamivudine—ABCG2—Dactinomycin—muscle cancer	0.0438	0.0566	CbGbCtD
Lamivudine—ABCC3—Doxorubicin—muscle cancer	0.0411	0.0531	CbGbCtD
Lamivudine—ABCC1—Vincristine—muscle cancer	0.0403	0.0521	CbGbCtD
Lamivudine—ABCC3—Methotrexate—muscle cancer	0.0398	0.0514	CbGbCtD
Lamivudine—ABCC1—Etoposide—muscle cancer	0.037	0.0478	CbGbCtD
Lamivudine—ABCC4—Methotrexate—muscle cancer	0.0304	0.0393	CbGbCtD
Lamivudine—ABCC2—Vincristine—muscle cancer	0.0298	0.0386	CbGbCtD
Lamivudine—ABCC2—Etoposide—muscle cancer	0.0274	0.0354	CbGbCtD
Lamivudine—ABCG2—Vincristine—muscle cancer	0.027	0.0349	CbGbCtD
Lamivudine—ABCC1—Doxorubicin—muscle cancer	0.0252	0.0326	CbGbCtD
Lamivudine—ABCG2—Etoposide—muscle cancer	0.0247	0.032	CbGbCtD
Lamivudine—ABCC1—Methotrexate—muscle cancer	0.0244	0.0316	CbGbCtD
Lamivudine—ABCC2—Doxorubicin—muscle cancer	0.0187	0.0241	CbGbCtD
Lamivudine—ABCC2—Methotrexate—muscle cancer	0.0181	0.0234	CbGbCtD
Lamivudine—ABCG2—Doxorubicin—muscle cancer	0.0169	0.0218	CbGbCtD
Lamivudine—ABCG2—Methotrexate—muscle cancer	0.0163	0.0211	CbGbCtD
Lamivudine—ABCB1—Dactinomycin—muscle cancer	0.0158	0.0204	CbGbCtD
Lamivudine—SLC22A6—Methotrexate—muscle cancer	0.0132	0.0171	CbGbCtD
Lamivudine—ABCB1—Vincristine—muscle cancer	0.00973	0.0126	CbGbCtD
Lamivudine—ABCB1—Etoposide—muscle cancer	0.00892	0.0115	CbGbCtD
Lamivudine—ABCB1—Doxorubicin—muscle cancer	0.00608	0.00786	CbGbCtD
Lamivudine—ABCB1—Methotrexate—muscle cancer	0.00589	0.00762	CbGbCtD
Lamivudine—NME2—Validated targets of C-MYC transcriptional activation—PTMA—muscle cancer	0.00507	0.13	CbGpPWpGaD
Lamivudine—PCYT2—renal system—muscle cancer	0.00401	0.0518	CbGeAlD
Lamivudine—NME1—Validated targets of C-MYC transcriptional activation—PTMA—muscle cancer	0.00384	0.0982	CbGpPWpGaD
Lamivudine—PGK1—Glycolysis—ENO2—muscle cancer	0.00354	0.0905	CbGpPWpGaD
Lamivudine—PGK1—Gluconeogenesis—ENO2—muscle cancer	0.00317	0.0811	CbGpPWpGaD
Lamivudine—NT5C—renal system—muscle cancer	0.00291	0.0376	CbGeAlD
Lamivudine—PCYT1A—renal system—muscle cancer	0.00273	0.0353	CbGeAlD
Lamivudine—PCYT2—head—muscle cancer	0.00268	0.0347	CbGeAlD
Lamivudine—PCYT2—testis—muscle cancer	0.00259	0.0335	CbGeAlD
Lamivudine—PGK1—head—muscle cancer	0.0023	0.0298	CbGeAlD
Lamivudine—NME2—embryo—muscle cancer	0.00227	0.0294	CbGeAlD
Lamivudine—NT5C—tendon—muscle cancer	0.00227	0.0294	CbGeAlD
Lamivudine—PGK1—testis—muscle cancer	0.00223	0.0288	CbGeAlD
Lamivudine—PGK1—Glycolysis and Gluconeogenesis—ENO2—muscle cancer	0.0022	0.0562	CbGpPWpGaD
Lamivudine—NT5C—vagina—muscle cancer	0.00211	0.0272	CbGeAlD
Lamivudine—NME1-NME2—head—muscle cancer	0.0021	0.0271	CbGeAlD
Lamivudine—NT5C—head—muscle cancer	0.00195	0.0252	CbGeAlD
Lamivudine—NT5C—testis—muscle cancer	0.00188	0.0243	CbGeAlD
Lamivudine—CMPK1—smooth muscle tissue—muscle cancer	0.00183	0.0236	CbGeAlD
Lamivudine—PCYT1A—head—muscle cancer	0.00183	0.0236	CbGeAlD
Lamivudine—NME1—renal system—muscle cancer	0.00182	0.0236	CbGeAlD
Lamivudine—PCYT1A—testis—muscle cancer	0.00176	0.0228	CbGeAlD
Lamivudine—CMPK1—renal system—muscle cancer	0.00176	0.0227	CbGeAlD
Lamivudine—NME2—renal system—muscle cancer	0.00172	0.0222	CbGeAlD
Lamivudine—PGK1—Glucose metabolism—ENO2—muscle cancer	0.00163	0.0418	CbGpPWpGaD
Lamivudine—CMPK1—cardiac atrium—muscle cancer	0.00157	0.0204	CbGeAlD
Lamivudine—NME1—bone marrow—muscle cancer	0.00138	0.0178	CbGeAlD
Lamivudine—CMPK1—bone marrow—muscle cancer	0.00133	0.0172	CbGeAlD
Lamivudine—DCK—Epirubicin—Doxorubicin—muscle cancer	0.00131	1	CbGdCrCtD
Lamivudine—CMPK1—vagina—muscle cancer	0.00127	0.0165	CbGeAlD
Lamivudine—NME1—head—muscle cancer	0.00122	0.0158	CbGeAlD
Lamivudine—NME1—testis—muscle cancer	0.00118	0.0152	CbGeAlD
Lamivudine—CMPK1—head—muscle cancer	0.00118	0.0152	CbGeAlD
Lamivudine—NME2—Validated targets of C-MYC transcriptional activation—HMGA1—muscle cancer	0.00116	0.0296	CbGpPWpGaD
Lamivudine—DCK—embryo—muscle cancer	0.00116	0.015	CbGeAlD
Lamivudine—NME2—head—muscle cancer	0.00115	0.0149	CbGeAlD
Lamivudine—CMPK1—testis—muscle cancer	0.00114	0.0147	CbGeAlD
Lamivudine—NME2—testis—muscle cancer	0.00111	0.0144	CbGeAlD
Lamivudine—SLC22A2—renal system—muscle cancer	0.00106	0.0137	CbGeAlD
Lamivudine—SLC22A3—embryo—muscle cancer	0.000943	0.0122	CbGeAlD
Lamivudine—NME1—Posttranslational regulation of adherens junction stability and dissassembly—IGF2—muscle cancer	0.000942	0.0241	CbGpPWpGaD
Lamivudine—NME1—Validated targets of C-MYC transcriptional activation—HMGA1—muscle cancer	0.000878	0.0225	CbGpPWpGaD
Lamivudine—ABCC3—renal system—muscle cancer	0.000838	0.0108	CbGeAlD
Lamivudine—PGK1—HIF-2-alpha transcription factor network—VEGFA—muscle cancer	0.000807	0.0207	CbGpPWpGaD
Lamivudine—DCK—cardiac atrium—muscle cancer	0.000784	0.0101	CbGeAlD
Lamivudine—SLC22A1—renal system—muscle cancer	0.000747	0.00966	CbGeAlD
Lamivudine—SLC22A3—smooth muscle tissue—muscle cancer	0.000741	0.00959	CbGeAlD
Lamivudine—SLC22A3—renal system—muscle cancer	0.000714	0.00923	CbGeAlD
Lamivudine—ABCC4—renal system—muscle cancer	0.000692	0.00895	CbGeAlD
Lamivudine—DCK—tendon—muscle cancer	0.000683	0.00884	CbGeAlD
Lamivudine—ABCC2—renal system—muscle cancer	0.00067	0.00866	CbGeAlD
Lamivudine—DCK—bone marrow—muscle cancer	0.000662	0.00856	CbGeAlD
Lamivudine—DCK—vagina—muscle cancer	0.000634	0.0082	CbGeAlD
Lamivudine—DCK—head—muscle cancer	0.000586	0.00757	CbGeAlD
Lamivudine—PGK1—Carbohydrate metabolism—ENO2—muscle cancer	0.00058	0.0148	CbGpPWpGaD
Lamivudine—DCK—testis—muscle cancer	0.000566	0.00732	CbGeAlD
Lamivudine—ABCC3—head—muscle cancer	0.000561	0.00725	CbGeAlD
Lamivudine—ABCC3—testis—muscle cancer	0.000542	0.00701	CbGeAlD
Lamivudine—SLC22A1—vagina—muscle cancer	0.000541	0.00699	CbGeAlD
Lamivudine—ABCC4—tendon—muscle cancer	0.00054	0.00698	CbGeAlD
Lamivudine—NME1—Integrated Pancreatic Cancer Pathway—WT1—muscle cancer	0.000532	0.0136	CbGpPWpGaD
Lamivudine—ABCC1—cardiac atrium—muscle cancer	0.000528	0.00683	CbGeAlD
Lamivudine—ABCC4—bone marrow—muscle cancer	0.000523	0.00676	CbGeAlD
Lamivudine—ABCC2—tendon—muscle cancer	0.000523	0.00676	CbGeAlD
Lamivudine—SLC22A3—vagina—muscle cancer	0.000517	0.00668	CbGeAlD
Lamivudine—ABCC4—Ectoderm Differentiation—PAX3—muscle cancer	0.000504	0.0129	CbGpPWpGaD
Lamivudine—SLC22A1—head—muscle cancer	0.0005	0.00646	CbGeAlD
Lamivudine—SLC22A3—head—muscle cancer	0.000477	0.00617	CbGeAlD
Lamivudine—ABCC3—Constitutive Androstane Receptor Pathway—FOXO1—muscle cancer	0.000477	0.0122	CbGpPWpGaD
Lamivudine—PGK1—HIF-1-alpha transcription factor network—VEGFA—muscle cancer	0.000475	0.0122	CbGpPWpGaD
Lamivudine—ABCC4—head—muscle cancer	0.000463	0.00599	CbGeAlD
Lamivudine—SLC22A3—testis—muscle cancer	0.000461	0.00596	CbGeAlD
Lamivudine—ABCC1—tendon—muscle cancer	0.000461	0.00595	CbGeAlD
Lamivudine—ABCC4—testis—muscle cancer	0.000447	0.00578	CbGeAlD
Lamivudine—ABCC2—testis—muscle cancer	0.000433	0.0056	CbGeAlD
Lamivudine—ABCC1—vagina—muscle cancer	0.000427	0.00553	CbGeAlD
Lamivudine—PCYT2—Metabolism of lipids and lipoproteins—MED12—muscle cancer	0.000416	0.0106	CbGpPWpGaD
Lamivudine—NME1—Integrated Pancreatic Cancer Pathway—BUB1B—muscle cancer	0.000389	0.00994	CbGpPWpGaD
Lamivudine—ABCC1—testis—muscle cancer	0.000381	0.00493	CbGeAlD
Lamivudine—ABCC2—Constitutive Androstane Receptor Pathway—FOXO1—muscle cancer	0.000378	0.00968	CbGpPWpGaD
Lamivudine—ABCG2—bone marrow—muscle cancer	0.000369	0.00478	CbGeAlD
Lamivudine—ABCG2—vagina—muscle cancer	0.000354	0.00457	CbGeAlD
Lamivudine—ABCC1—S1P1 pathway—PTGS2—muscle cancer	0.000328	0.0084	CbGpPWpGaD
Lamivudine—NT5C—Metabolism—FH—muscle cancer	0.000328	0.00838	CbGpPWpGaD
Lamivudine—PCYT2—Metabolism—FH—muscle cancer	0.000328	0.00838	CbGpPWpGaD
Lamivudine—CMPK1—Metabolism—FH—muscle cancer	0.000328	0.00838	CbGpPWpGaD
Lamivudine—ABCC4—Ectoderm Differentiation—DMD—muscle cancer	0.00032	0.00819	CbGpPWpGaD
Lamivudine—ABCB1—embryo—muscle cancer	0.000318	0.00411	CbGeAlD
Lamivudine—ABCG2—testis—muscle cancer	0.000316	0.00408	CbGeAlD
Lamivudine—PCYT1A—Metabolism of lipids and lipoproteins—MED12—muscle cancer	0.000315	0.00806	CbGpPWpGaD
Lamivudine—PGK1—Metabolism—FH—muscle cancer	0.000267	0.00683	CbGpPWpGaD
Lamivudine—NME2—Validated targets of C-MYC transcriptional activation—TP53—muscle cancer	0.000264	0.00676	CbGpPWpGaD
Lamivudine—ABCC1—S1P1 pathway—VEGFA—muscle cancer	0.000259	0.00661	CbGpPWpGaD
Lamivudine—PCYT1A—Metabolism—FH—muscle cancer	0.000248	0.00635	CbGpPWpGaD
Lamivudine—ABCB1—renal system—muscle cancer	0.000241	0.00311	CbGeAlD
Lamivudine—ABCC4—Platelet degranulation—IGF2—muscle cancer	0.000234	0.00599	CbGpPWpGaD
Lamivudine—Muscle spasms—Etoposide—muscle cancer	0.000232	0.00213	CcSEcCtD
Lamivudine—Anorexia—Vincristine—muscle cancer	0.000231	0.00213	CcSEcCtD
Lamivudine—NME2—Metabolism—FH—muscle cancer	0.000227	0.00581	CbGpPWpGaD
Lamivudine—Mood swings—Methotrexate—muscle cancer	0.000227	0.00209	CcSEcCtD
Lamivudine—Hypotension—Vincristine—muscle cancer	0.000227	0.00209	CcSEcCtD
Lamivudine—Feeling abnormal—Dactinomycin—muscle cancer	0.000224	0.00206	CcSEcCtD
Lamivudine—Ill-defined disorder—Etoposide—muscle cancer	0.000223	0.00206	CcSEcCtD
Lamivudine—ABCC4—Response to elevated platelet cytosolic Ca2+—IGF2—muscle cancer	0.000223	0.00571	CbGpPWpGaD
Lamivudine—Anaemia—Etoposide—muscle cancer	0.000223	0.00205	CcSEcCtD
Lamivudine—Gastrointestinal pain—Dactinomycin—muscle cancer	0.000222	0.00204	CcSEcCtD
Lamivudine—DCK—Retinoblastoma (RB) in Cancer—MDM2—muscle cancer	0.000222	0.00567	CbGpPWpGaD
Lamivudine—Liver function test abnormal—Methotrexate—muscle cancer	0.000221	0.00203	CcSEcCtD
Lamivudine—Musculoskeletal discomfort—Vincristine—muscle cancer	0.000221	0.00203	CcSEcCtD
Lamivudine—Insomnia—Vincristine—muscle cancer	0.000219	0.00202	CcSEcCtD
Lamivudine—Renal impairment—Doxorubicin—muscle cancer	0.000218	0.002	CcSEcCtD
Lamivudine—Paraesthesia—Vincristine—muscle cancer	0.000218	0.002	CcSEcCtD
Lamivudine—Malaise—Etoposide—muscle cancer	0.000217	0.002	CcSEcCtD
Lamivudine—Vertigo—Etoposide—muscle cancer	0.000216	0.00199	CcSEcCtD
Lamivudine—Leukopenia—Etoposide—muscle cancer	0.000216	0.00198	CcSEcCtD
Lamivudine—Abdominal pain—Dactinomycin—muscle cancer	0.000215	0.00197	CcSEcCtD
Lamivudine—Body temperature increased—Dactinomycin—muscle cancer	0.000215	0.00197	CcSEcCtD
Lamivudine—Hypoglycaemia—Doxorubicin—muscle cancer	0.000213	0.00195	CcSEcCtD
Lamivudine—Loss of consciousness—Etoposide—muscle cancer	0.000212	0.00195	CcSEcCtD
Lamivudine—Decreased appetite—Vincristine—muscle cancer	0.000211	0.00194	CcSEcCtD
Lamivudine—Cough—Etoposide—muscle cancer	0.00021	0.00193	CcSEcCtD
Lamivudine—Gastrointestinal disorder—Vincristine—muscle cancer	0.000209	0.00193	CcSEcCtD
Lamivudine—Fatigue—Vincristine—muscle cancer	0.000209	0.00192	CcSEcCtD
Lamivudine—Convulsion—Etoposide—muscle cancer	0.000209	0.00192	CcSEcCtD
Lamivudine—Constipation—Vincristine—muscle cancer	0.000207	0.00191	CcSEcCtD
Lamivudine—Pain—Vincristine—muscle cancer	0.000207	0.00191	CcSEcCtD
Lamivudine—Chest pain—Etoposide—muscle cancer	0.000205	0.00189	CcSEcCtD
Lamivudine—Affect lability—Doxorubicin—muscle cancer	0.000204	0.00188	CcSEcCtD
Lamivudine—Migraine—Doxorubicin—muscle cancer	0.000204	0.00188	CcSEcCtD
Lamivudine—Unspecified disorder of skin and subcutaneous tissue—Etoposide—muscle cancer	0.000204	0.00187	CcSEcCtD
Lamivudine—Pancreatitis—Methotrexate—muscle cancer	0.000203	0.00187	CcSEcCtD
Lamivudine—Discomfort—Etoposide—muscle cancer	0.000203	0.00186	CcSEcCtD
Lamivudine—NME1—Validated targets of C-MYC transcriptional activation—TP53—muscle cancer	0.0002	0.00512	CbGpPWpGaD
Lamivudine—Hypersensitivity—Dactinomycin—muscle cancer	0.0002	0.00184	CcSEcCtD
Lamivudine—Abdominal discomfort—Methotrexate—muscle cancer	0.000198	0.00183	CcSEcCtD
Lamivudine—Gastrointestinal pain—Vincristine—muscle cancer	0.000198	0.00182	CcSEcCtD
Lamivudine—Confusional state—Etoposide—muscle cancer	0.000198	0.00182	CcSEcCtD
Lamivudine—Pancytopenia—Methotrexate—muscle cancer	0.000197	0.00181	CcSEcCtD
Lamivudine—Anaphylactic shock—Etoposide—muscle cancer	0.000197	0.00181	CcSEcCtD
Lamivudine—Mood swings—Doxorubicin—muscle cancer	0.000196	0.00181	CcSEcCtD
Lamivudine—Infection—Etoposide—muscle cancer	0.000195	0.0018	CcSEcCtD
Lamivudine—Asthenia—Dactinomycin—muscle cancer	0.000195	0.00179	CcSEcCtD
Lamivudine—Dysuria—Methotrexate—muscle cancer	0.000194	0.00178	CcSEcCtD
Lamivudine—Neutropenia—Methotrexate—muscle cancer	0.000194	0.00178	CcSEcCtD
Lamivudine—Dehydration—Doxorubicin—muscle cancer	0.000193	0.00177	CcSEcCtD
Lamivudine—Thrombocytopenia—Etoposide—muscle cancer	0.000192	0.00177	CcSEcCtD
Lamivudine—Body temperature increased—Vincristine—muscle cancer	0.000192	0.00176	CcSEcCtD
Lamivudine—Abdominal pain—Vincristine—muscle cancer	0.000192	0.00176	CcSEcCtD
Lamivudine—Liver function test abnormal—Doxorubicin—muscle cancer	0.000191	0.00176	CcSEcCtD
Lamivudine—Skin disorder—Etoposide—muscle cancer	0.000191	0.00176	CcSEcCtD
Lamivudine—Hyperhidrosis—Etoposide—muscle cancer	0.00019	0.00175	CcSEcCtD
Lamivudine—Abdominal pain upper—Doxorubicin—muscle cancer	0.000189	0.00174	CcSEcCtD
Lamivudine—Anorexia—Etoposide—muscle cancer	0.000187	0.00172	CcSEcCtD
Lamivudine—Aspartate aminotransferase increased—Doxorubicin—muscle cancer	0.000187	0.00172	CcSEcCtD
Lamivudine—Diarrhoea—Dactinomycin—muscle cancer	0.000186	0.00171	CcSEcCtD
Lamivudine—Nasopharyngitis—Doxorubicin—muscle cancer	0.000185	0.00171	CcSEcCtD
Lamivudine—CMPK1—Metabolism—MED12—muscle cancer	0.000185	0.00474	CbGpPWpGaD
Lamivudine—PCYT2—Metabolism—MED12—muscle cancer	0.000185	0.00474	CbGpPWpGaD
Lamivudine—NT5C—Metabolism—MED12—muscle cancer	0.000185	0.00474	CbGpPWpGaD
Lamivudine—Depression—Methotrexate—muscle cancer	0.000184	0.00169	CcSEcCtD
Lamivudine—Hypotension—Etoposide—muscle cancer	0.000184	0.00169	CcSEcCtD
Lamivudine—Stevens-Johnson syndrome—Methotrexate—muscle cancer	0.000183	0.00168	CcSEcCtD
Lamivudine—Alanine aminotransferase increased—Doxorubicin—muscle cancer	0.000183	0.00168	CcSEcCtD
Lamivudine—Muscular weakness—Doxorubicin—muscle cancer	0.000183	0.00168	CcSEcCtD
Lamivudine—ABCB1—bone marrow—muscle cancer	0.000182	0.00235	CbGeAlD
Lamivudine—Renal failure—Methotrexate—muscle cancer	0.000181	0.00167	CcSEcCtD
Lamivudine—Abdominal distension—Doxorubicin—muscle cancer	0.00018	0.00166	CcSEcCtD
Lamivudine—Stomatitis—Methotrexate—muscle cancer	0.00018	0.00166	CcSEcCtD
Lamivudine—Dysphagia—Doxorubicin—muscle cancer	0.000179	0.00165	CcSEcCtD
Lamivudine—Influenza—Doxorubicin—muscle cancer	0.000179	0.00165	CcSEcCtD
Lamivudine—Hypersensitivity—Vincristine—muscle cancer	0.000179	0.00164	CcSEcCtD
Lamivudine—ABCG2—Imatinib Resistance in Chronic Myeloid Leukemia—KIT—muscle cancer	0.000178	0.00456	CbGpPWpGaD
Lamivudine—ABCB1—Constitutive Androstane Receptor Pathway—FOXO1—muscle cancer	0.000178	0.00455	CbGpPWpGaD
Lamivudine—Sweating—Methotrexate—muscle cancer	0.000177	0.00163	CcSEcCtD
Lamivudine—Paraesthesia—Etoposide—muscle cancer	0.000176	0.00162	CcSEcCtD
Lamivudine—Pancreatitis—Doxorubicin—muscle cancer	0.000176	0.00162	CcSEcCtD
Lamivudine—Dyspnoea—Etoposide—muscle cancer	0.000175	0.00161	CcSEcCtD
Lamivudine—Somnolence—Etoposide—muscle cancer	0.000175	0.00161	CcSEcCtD
Lamivudine—Hepatobiliary disease—Methotrexate—muscle cancer	0.000175	0.00161	CcSEcCtD
Lamivudine—ABCB1—vagina—muscle cancer	0.000174	0.00226	CbGeAlD
Lamivudine—Epistaxis—Methotrexate—muscle cancer	0.000174	0.0016	CcSEcCtD
Lamivudine—Asthenia—Vincristine—muscle cancer	0.000174	0.0016	CcSEcCtD
Lamivudine—Vomiting—Dactinomycin—muscle cancer	0.000173	0.00159	CcSEcCtD
Lamivudine—Bronchitis—Doxorubicin—muscle cancer	0.000172	0.00159	CcSEcCtD
Lamivudine—NME1—Integrated Pancreatic Cancer Pathway—MDM2—muscle cancer	0.000172	0.00441	CbGpPWpGaD
Lamivudine—Agranulocytosis—Methotrexate—muscle cancer	0.000172	0.00158	CcSEcCtD
Lamivudine—NME1—Metabolism—FH—muscle cancer	0.000172	0.0044	CbGpPWpGaD
Lamivudine—Rash—Dactinomycin—muscle cancer	0.000171	0.00157	CcSEcCtD
Lamivudine—Decreased appetite—Etoposide—muscle cancer	0.000171	0.00157	CcSEcCtD
Lamivudine—Pancytopenia—Doxorubicin—muscle cancer	0.00017	0.00157	CcSEcCtD
Lamivudine—Gastrointestinal disorder—Etoposide—muscle cancer	0.00017	0.00156	CcSEcCtD
Lamivudine—Fatigue—Etoposide—muscle cancer	0.000169	0.00156	CcSEcCtD
Lamivudine—CMPK1—Metabolism—ENO2—muscle cancer	0.000169	0.00432	CbGpPWpGaD
Lamivudine—PCYT2—Metabolism—ENO2—muscle cancer	0.000169	0.00432	CbGpPWpGaD
Lamivudine—NT5C—Metabolism—ENO2—muscle cancer	0.000169	0.00432	CbGpPWpGaD
Lamivudine—Pain—Etoposide—muscle cancer	0.000168	0.00155	CcSEcCtD
Lamivudine—Constipation—Etoposide—muscle cancer	0.000168	0.00155	CcSEcCtD
Lamivudine—Dysuria—Doxorubicin—muscle cancer	0.000168	0.00154	CcSEcCtD
Lamivudine—Neutropenia—Doxorubicin—muscle cancer	0.000168	0.00154	CcSEcCtD
Lamivudine—NME1—Integrated Pancreatic Cancer Pathway—PTGS2—muscle cancer	0.000166	0.00425	CbGpPWpGaD
Lamivudine—Diarrhoea—Vincristine—muscle cancer	0.000166	0.00153	CcSEcCtD
Lamivudine—Hepatitis—Methotrexate—muscle cancer	0.000166	0.00152	CcSEcCtD
Lamivudine—Pollakiuria—Doxorubicin—muscle cancer	0.000166	0.00152	CcSEcCtD
Lamivudine—Pharyngitis—Methotrexate—muscle cancer	0.000164	0.00151	CcSEcCtD
Lamivudine—PGK1—Disease—ENO2—muscle cancer	0.000164	0.0042	CbGpPWpGaD
Lamivudine—Feeling abnormal—Etoposide—muscle cancer	0.000162	0.00149	CcSEcCtD
Lamivudine—Hyperglycaemia—Doxorubicin—muscle cancer	0.000162	0.00149	CcSEcCtD
Lamivudine—Nausea—Dactinomycin—muscle cancer	0.000161	0.00148	CcSEcCtD
Lamivudine—ABCB1—head—muscle cancer	0.000161	0.00208	CbGeAlD
Lamivudine—Gastrointestinal pain—Etoposide—muscle cancer	0.000161	0.00148	CcSEcCtD
Lamivudine—Dizziness—Vincristine—muscle cancer	0.00016	0.00148	CcSEcCtD
Lamivudine—ABCC3—Fluoropyrimidine Activity—TP53—muscle cancer	0.00016	0.0041	CbGpPWpGaD
Lamivudine—Stevens-Johnson syndrome—Doxorubicin—muscle cancer	0.000158	0.00146	CcSEcCtD
Lamivudine—Renal failure—Doxorubicin—muscle cancer	0.000157	0.00145	CcSEcCtD
Lamivudine—Erythema multiforme—Methotrexate—muscle cancer	0.000157	0.00144	CcSEcCtD
Lamivudine—Neuropathy peripheral—Doxorubicin—muscle cancer	0.000157	0.00144	CcSEcCtD
Lamivudine—Urticaria—Etoposide—muscle cancer	0.000156	0.00144	CcSEcCtD
Lamivudine—Jaundice—Doxorubicin—muscle cancer	0.000156	0.00143	CcSEcCtD
Lamivudine—Stomatitis—Doxorubicin—muscle cancer	0.000156	0.00143	CcSEcCtD
Lamivudine—ABCB1—testis—muscle cancer	0.000156	0.00201	CbGeAlD
Lamivudine—Body temperature increased—Etoposide—muscle cancer	0.000155	0.00143	CcSEcCtD
Lamivudine—Abdominal pain—Etoposide—muscle cancer	0.000155	0.00143	CcSEcCtD
Lamivudine—Vomiting—Vincristine—muscle cancer	0.000154	0.00142	CcSEcCtD
Lamivudine—Sweating—Doxorubicin—muscle cancer	0.000153	0.00141	CcSEcCtD
Lamivudine—Rash—Vincristine—muscle cancer	0.000153	0.00141	CcSEcCtD
Lamivudine—Dermatitis—Vincristine—muscle cancer	0.000153	0.00141	CcSEcCtD
Lamivudine—Headache—Vincristine—muscle cancer	0.000152	0.0014	CcSEcCtD
Lamivudine—ABCC1—Arachidonic acid metabolism—PTGS2—muscle cancer	0.000151	0.00387	CbGpPWpGaD
Lamivudine—Hepatobiliary disease—Doxorubicin—muscle cancer	0.000151	0.00139	CcSEcCtD
Lamivudine—PGK1—Metabolism—MED12—muscle cancer	0.000151	0.00386	CbGpPWpGaD
Lamivudine—Epistaxis—Doxorubicin—muscle cancer	0.000151	0.00139	CcSEcCtD
Lamivudine—ABCC4—Fluoropyrimidine Activity—TP53—muscle cancer	0.000151	0.00386	CbGpPWpGaD
Lamivudine—Sinusitis—Doxorubicin—muscle cancer	0.00015	0.00138	CcSEcCtD
Lamivudine—Immune system disorder—Methotrexate—muscle cancer	0.00015	0.00138	CcSEcCtD
Lamivudine—Mediastinal disorder—Methotrexate—muscle cancer	0.000149	0.00137	CcSEcCtD
Lamivudine—PGK1—Disease—HMGA1—muscle cancer	0.000149	0.00382	CbGpPWpGaD
Lamivudine—Agranulocytosis—Doxorubicin—muscle cancer	0.000149	0.00137	CcSEcCtD
Lamivudine—Chills—Methotrexate—muscle cancer	0.000149	0.00137	CcSEcCtD
Lamivudine—Alopecia—Methotrexate—muscle cancer	0.000146	0.00135	CcSEcCtD
Lamivudine—Hypersensitivity—Etoposide—muscle cancer	0.000145	0.00133	CcSEcCtD
Lamivudine—Erythema—Methotrexate—muscle cancer	0.000144	0.00133	CcSEcCtD
Lamivudine—Malnutrition—Methotrexate—muscle cancer	0.000144	0.00133	CcSEcCtD
Lamivudine—Nausea—Vincristine—muscle cancer	0.000144	0.00133	CcSEcCtD
Lamivudine—Rhinitis—Doxorubicin—muscle cancer	0.000144	0.00132	CcSEcCtD
Lamivudine—Hepatitis—Doxorubicin—muscle cancer	0.000143	0.00132	CcSEcCtD
Lamivudine—ABCG2—HIF-2-alpha transcription factor network—VEGFA—muscle cancer	0.000143	0.00365	CbGpPWpGaD
Lamivudine—Hypoaesthesia—Doxorubicin—muscle cancer	0.000143	0.00131	CcSEcCtD
Lamivudine—Pharyngitis—Doxorubicin—muscle cancer	0.000142	0.00131	CcSEcCtD
Lamivudine—Dysgeusia—Methotrexate—muscle cancer	0.000141	0.0013	CcSEcCtD
Lamivudine—Asthenia—Etoposide—muscle cancer	0.000141	0.0013	CcSEcCtD
Lamivudine—Connective tissue disorder—Doxorubicin—muscle cancer	0.000141	0.0013	CcSEcCtD
Lamivudine—PCYT1A—Metabolism—MED12—muscle cancer	0.00014	0.00359	CbGpPWpGaD
Lamivudine—Back pain—Methotrexate—muscle cancer	0.00014	0.00128	CcSEcCtD
Lamivudine—Pruritus—Etoposide—muscle cancer	0.000139	0.00128	CcSEcCtD
Lamivudine—PGK1—Metabolism—ENO2—muscle cancer	0.000138	0.00352	CbGpPWpGaD
Lamivudine—Erythema multiforme—Doxorubicin—muscle cancer	0.000136	0.00125	CcSEcCtD
Lamivudine—Diarrhoea—Etoposide—muscle cancer	0.000134	0.00124	CcSEcCtD
Lamivudine—PGK1—Disease—FOXO4—muscle cancer	0.000134	0.00343	CbGpPWpGaD
Lamivudine—Ill-defined disorder—Methotrexate—muscle cancer	0.000134	0.00123	CcSEcCtD
Lamivudine—Anaemia—Methotrexate—muscle cancer	0.000133	0.00123	CcSEcCtD
Lamivudine—PCYT2—Metabolism of lipids and lipoproteins—PTGS2—muscle cancer	0.000132	0.00338	CbGpPWpGaD
Lamivudine—NME1—Integrated Pancreatic Cancer Pathway—VEGFA—muscle cancer	0.000131	0.00335	CbGpPWpGaD
Lamivudine—Malaise—Methotrexate—muscle cancer	0.00013	0.0012	CcSEcCtD
Lamivudine—Dizziness—Etoposide—muscle cancer	0.00013	0.0012	CcSEcCtD
Lamivudine—Immune system disorder—Doxorubicin—muscle cancer	0.00013	0.00119	CcSEcCtD
Lamivudine—Vertigo—Methotrexate—muscle cancer	0.00013	0.00119	CcSEcCtD
Lamivudine—Mediastinal disorder—Doxorubicin—muscle cancer	0.000129	0.00119	CcSEcCtD
Lamivudine—Leukopenia—Methotrexate—muscle cancer	0.000129	0.00119	CcSEcCtD
Lamivudine—Chills—Doxorubicin—muscle cancer	0.000129	0.00118	CcSEcCtD
Lamivudine—NME2—Metabolism—MED12—muscle cancer	0.000128	0.00328	CbGpPWpGaD
Lamivudine—PCYT1A—Metabolism—ENO2—muscle cancer	0.000128	0.00327	CbGpPWpGaD
Lamivudine—DCK—Retinoblastoma (RB) in Cancer—TP53—muscle cancer	0.000127	0.00325	CbGpPWpGaD
Lamivudine—Alopecia—Doxorubicin—muscle cancer	0.000127	0.00117	CcSEcCtD
Lamivudine—Cough—Methotrexate—muscle cancer	0.000126	0.00116	CcSEcCtD
Lamivudine—Convulsion—Methotrexate—muscle cancer	0.000125	0.00115	CcSEcCtD
Lamivudine—Vomiting—Etoposide—muscle cancer	0.000125	0.00115	CcSEcCtD
Lamivudine—Malnutrition—Doxorubicin—muscle cancer	0.000125	0.00115	CcSEcCtD
Lamivudine—Erythema—Doxorubicin—muscle cancer	0.000125	0.00115	CcSEcCtD
Lamivudine—Rash—Etoposide—muscle cancer	0.000124	0.00114	CcSEcCtD
Lamivudine—Dermatitis—Etoposide—muscle cancer	0.000124	0.00114	CcSEcCtD
Lamivudine—Headache—Etoposide—muscle cancer	0.000123	0.00113	CcSEcCtD
Lamivudine—Flatulence—Doxorubicin—muscle cancer	0.000123	0.00113	CcSEcCtD
Lamivudine—Myalgia—Methotrexate—muscle cancer	0.000123	0.00113	CcSEcCtD
Lamivudine—Chest pain—Methotrexate—muscle cancer	0.000123	0.00113	CcSEcCtD
Lamivudine—Arthralgia—Methotrexate—muscle cancer	0.000123	0.00113	CcSEcCtD
Lamivudine—Tension—Doxorubicin—muscle cancer	0.000123	0.00113	CcSEcCtD
Lamivudine—Dysgeusia—Doxorubicin—muscle cancer	0.000122	0.00113	CcSEcCtD
Lamivudine—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—muscle cancer	0.000122	0.00112	CcSEcCtD
Lamivudine—Discomfort—Methotrexate—muscle cancer	0.000121	0.00112	CcSEcCtD
Lamivudine—Nervousness—Doxorubicin—muscle cancer	0.000121	0.00112	CcSEcCtD
Lamivudine—Back pain—Doxorubicin—muscle cancer	0.000121	0.00111	CcSEcCtD
Lamivudine—Muscle spasms—Doxorubicin—muscle cancer	0.00012	0.0011	CcSEcCtD
Lamivudine—Confusional state—Methotrexate—muscle cancer	0.000119	0.00109	CcSEcCtD
Lamivudine—DCK—Metabolism—FH—muscle cancer	0.000118	0.00302	CbGpPWpGaD
Lamivudine—Anaphylactic shock—Methotrexate—muscle cancer	0.000118	0.00108	CcSEcCtD
Lamivudine—NME2—Metabolism—ENO2—muscle cancer	0.000117	0.00299	CbGpPWpGaD
Lamivudine—Infection—Methotrexate—muscle cancer	0.000117	0.00108	CcSEcCtD
Lamivudine—Nausea—Etoposide—muscle cancer	0.000117	0.00107	CcSEcCtD
Lamivudine—Ill-defined disorder—Doxorubicin—muscle cancer	0.000116	0.00107	CcSEcCtD
Lamivudine—Nervous system disorder—Methotrexate—muscle cancer	0.000115	0.00106	CcSEcCtD
Lamivudine—Anaemia—Doxorubicin—muscle cancer	0.000115	0.00106	CcSEcCtD
Lamivudine—Thrombocytopenia—Methotrexate—muscle cancer	0.000115	0.00106	CcSEcCtD
Lamivudine—Skin disorder—Methotrexate—muscle cancer	0.000114	0.00105	CcSEcCtD
Lamivudine—Hyperhidrosis—Methotrexate—muscle cancer	0.000114	0.00105	CcSEcCtD
Lamivudine—Malaise—Doxorubicin—muscle cancer	0.000113	0.00104	CcSEcCtD
Lamivudine—Vertigo—Doxorubicin—muscle cancer	0.000112	0.00103	CcSEcCtD
Lamivudine—Anorexia—Methotrexate—muscle cancer	0.000112	0.00103	CcSEcCtD
Lamivudine—Syncope—Doxorubicin—muscle cancer	0.000112	0.00103	CcSEcCtD
Lamivudine—Leukopenia—Doxorubicin—muscle cancer	0.000112	0.00103	CcSEcCtD
Lamivudine—ABCG2—Fluoropyrimidine Activity—TP53—muscle cancer	0.000111	0.00283	CbGpPWpGaD
Lamivudine—ABCC4—Hemostasis—ANGPT2—muscle cancer	0.00011	0.00282	CbGpPWpGaD
Lamivudine—Hypotension—Methotrexate—muscle cancer	0.00011	0.00101	CcSEcCtD
Lamivudine—Loss of consciousness—Doxorubicin—muscle cancer	0.00011	0.00101	CcSEcCtD
Lamivudine—Cough—Doxorubicin—muscle cancer	0.000109	0.001	CcSEcCtD
Lamivudine—Convulsion—Doxorubicin—muscle cancer	0.000108	0.000995	CcSEcCtD
Lamivudine—Musculoskeletal discomfort—Methotrexate—muscle cancer	0.000107	0.000987	CcSEcCtD
Lamivudine—Insomnia—Methotrexate—muscle cancer	0.000106	0.000979	CcSEcCtD
Lamivudine—Arthralgia—Doxorubicin—muscle cancer	0.000106	0.000978	CcSEcCtD
Lamivudine—Myalgia—Doxorubicin—muscle cancer	0.000106	0.000978	CcSEcCtD
Lamivudine—Chest pain—Doxorubicin—muscle cancer	0.000106	0.000978	CcSEcCtD
Lamivudine—Anxiety—Doxorubicin—muscle cancer	0.000106	0.000975	CcSEcCtD
Lamivudine—Paraesthesia—Methotrexate—muscle cancer	0.000106	0.000972	CcSEcCtD
Lamivudine—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—muscle cancer	0.000106	0.000971	CcSEcCtD
Lamivudine—Discomfort—Doxorubicin—muscle cancer	0.000105	0.000966	CcSEcCtD
Lamivudine—Dyspnoea—Methotrexate—muscle cancer	0.000105	0.000965	CcSEcCtD
Lamivudine—Somnolence—Methotrexate—muscle cancer	0.000105	0.000963	CcSEcCtD
Lamivudine—Dry mouth—Doxorubicin—muscle cancer	0.000104	0.000957	CcSEcCtD
Lamivudine—ABCC4—Platelet activation, signaling and aggregation—IGF2—muscle cancer	0.000104	0.00266	CbGpPWpGaD
Lamivudine—Dyspepsia—Methotrexate—muscle cancer	0.000104	0.000953	CcSEcCtD
Lamivudine—Confusional state—Doxorubicin—muscle cancer	0.000103	0.000945	CcSEcCtD
Lamivudine—Decreased appetite—Methotrexate—muscle cancer	0.000102	0.000941	CcSEcCtD
Lamivudine—Anaphylactic shock—Doxorubicin—muscle cancer	0.000102	0.000938	CcSEcCtD
Lamivudine—Oedema—Doxorubicin—muscle cancer	0.000102	0.000938	CcSEcCtD
Lamivudine—Gastrointestinal disorder—Methotrexate—muscle cancer	0.000102	0.000935	CcSEcCtD
Lamivudine—Fatigue—Methotrexate—muscle cancer	0.000101	0.000934	CcSEcCtD
Lamivudine—Infection—Doxorubicin—muscle cancer	0.000101	0.000932	CcSEcCtD
Lamivudine—Pain—Methotrexate—muscle cancer	0.000101	0.000926	CcSEcCtD
Lamivudine—Shock—Doxorubicin—muscle cancer	0.0001	0.000923	CcSEcCtD
Lamivudine—PCYT1A—Metabolism of lipids and lipoproteins—PTGS2—muscle cancer	0.0001	0.00256	CbGpPWpGaD
Lamivudine—Nervous system disorder—Doxorubicin—muscle cancer	0.0001	0.00092	CcSEcCtD
Lamivudine—Thrombocytopenia—Doxorubicin—muscle cancer	9.98e-05	0.000918	CcSEcCtD
Lamivudine—Skin disorder—Doxorubicin—muscle cancer	9.9e-05	0.000911	CcSEcCtD
Lamivudine—PGK1—Disease—FOXO1—muscle cancer	9.89e-05	0.00253	CbGpPWpGaD
Lamivudine—NME1—Integrated Pancreatic Cancer Pathway—TP53—muscle cancer	9.88e-05	0.00253	CbGpPWpGaD
Lamivudine—Hyperhidrosis—Doxorubicin—muscle cancer	9.85e-05	0.000906	CcSEcCtD
Lamivudine—ABCC4—Platelet degranulation—VEGFA—muscle cancer	9.82e-05	0.00251	CbGpPWpGaD
Lamivudine—NME1—Metabolism—MED12—muscle cancer	9.73e-05	0.00249	CbGpPWpGaD
Lamivudine—ABCC1—Defective AMN causes hereditary megaloblastic anemia 1—PTGS2—muscle cancer	9.72e-05	0.00249	CbGpPWpGaD
Lamivudine—Anorexia—Doxorubicin—muscle cancer	9.72e-05	0.000894	CcSEcCtD
Lamivudine—Feeling abnormal—Methotrexate—muscle cancer	9.7e-05	0.000892	CcSEcCtD
Lamivudine—ABCB1—Imatinib Resistance in Chronic Myeloid Leukemia—KIT—muscle cancer	9.64e-05	0.00247	CbGpPWpGaD
Lamivudine—Gastrointestinal pain—Methotrexate—muscle cancer	9.63e-05	0.000886	CcSEcCtD
Lamivudine—Hypotension—Doxorubicin—muscle cancer	9.53e-05	0.000876	CcSEcCtD
Lamivudine—ABCC4—Response to elevated platelet cytosolic Ca2+—VEGFA—muscle cancer	9.36e-05	0.00239	CbGpPWpGaD
Lamivudine—Urticaria—Methotrexate—muscle cancer	9.35e-05	0.00086	CcSEcCtD
Lamivudine—Abdominal pain—Methotrexate—muscle cancer	9.31e-05	0.000856	CcSEcCtD
Lamivudine—Body temperature increased—Methotrexate—muscle cancer	9.31e-05	0.000856	CcSEcCtD
Lamivudine—Musculoskeletal discomfort—Doxorubicin—muscle cancer	9.29e-05	0.000854	CcSEcCtD
Lamivudine—Insomnia—Doxorubicin—muscle cancer	9.22e-05	0.000848	CcSEcCtD
Lamivudine—Paraesthesia—Doxorubicin—muscle cancer	9.15e-05	0.000842	CcSEcCtD
Lamivudine—Dyspnoea—Doxorubicin—muscle cancer	9.09e-05	0.000836	CcSEcCtD
Lamivudine—Somnolence—Doxorubicin—muscle cancer	9.06e-05	0.000834	CcSEcCtD
Lamivudine—Dyspepsia—Doxorubicin—muscle cancer	8.97e-05	0.000825	CcSEcCtD
Lamivudine—NME1—Metabolism—ENO2—muscle cancer	8.87e-05	0.00227	CbGpPWpGaD
Lamivudine—Decreased appetite—Doxorubicin—muscle cancer	8.86e-05	0.000815	CcSEcCtD
Lamivudine—Gastrointestinal disorder—Doxorubicin—muscle cancer	8.8e-05	0.00081	CcSEcCtD
Lamivudine—Fatigue—Doxorubicin—muscle cancer	8.79e-05	0.000808	CcSEcCtD
Lamivudine—Pain—Doxorubicin—muscle cancer	8.72e-05	0.000802	CcSEcCtD
Lamivudine—Constipation—Doxorubicin—muscle cancer	8.72e-05	0.000802	CcSEcCtD
Lamivudine—ABCC3—Metabolism of lipids and lipoproteins—MED12—muscle cancer	8.69e-05	0.00222	CbGpPWpGaD
Lamivudine—Hypersensitivity—Methotrexate—muscle cancer	8.67e-05	0.000798	CcSEcCtD
Lamivudine—Asthenia—Methotrexate—muscle cancer	8.45e-05	0.000777	CcSEcCtD
Lamivudine—ABCG2—HIF-1-alpha transcription factor network—VEGFA—muscle cancer	8.4e-05	0.00215	CbGpPWpGaD
Lamivudine—Feeling abnormal—Doxorubicin—muscle cancer	8.4e-05	0.000773	CcSEcCtD
Lamivudine—Gastrointestinal pain—Doxorubicin—muscle cancer	8.34e-05	0.000767	CcSEcCtD
Lamivudine—Pruritus—Methotrexate—muscle cancer	8.33e-05	0.000766	CcSEcCtD
Lamivudine—Urticaria—Doxorubicin—muscle cancer	8.1e-05	0.000745	CcSEcCtD
Lamivudine—Body temperature increased—Doxorubicin—muscle cancer	8.06e-05	0.000741	CcSEcCtD
Lamivudine—Abdominal pain—Doxorubicin—muscle cancer	8.06e-05	0.000741	CcSEcCtD
Lamivudine—Diarrhoea—Methotrexate—muscle cancer	8.05e-05	0.000741	CcSEcCtD
Lamivudine—ABCB1—Integrated Pancreatic Cancer Pathway—WT1—muscle cancer	7.89e-05	0.00202	CbGpPWpGaD
Lamivudine—Dizziness—Methotrexate—muscle cancer	7.78e-05	0.000716	CcSEcCtD
Lamivudine—PGK1—Disease—KIT—muscle cancer	7.54e-05	0.00193	CbGpPWpGaD
Lamivudine—Hypersensitivity—Doxorubicin—muscle cancer	7.51e-05	0.000691	CcSEcCtD
Lamivudine—Vomiting—Methotrexate—muscle cancer	7.49e-05	0.000689	CcSEcCtD
Lamivudine—SLC22A3—Metabolism—FH—muscle cancer	7.46e-05	0.00191	CbGpPWpGaD
Lamivudine—Rash—Methotrexate—muscle cancer	7.42e-05	0.000683	CcSEcCtD
Lamivudine—Dermatitis—Methotrexate—muscle cancer	7.42e-05	0.000682	CcSEcCtD
Lamivudine—Headache—Methotrexate—muscle cancer	7.38e-05	0.000678	CcSEcCtD
Lamivudine—Asthenia—Doxorubicin—muscle cancer	7.31e-05	0.000673	CcSEcCtD
Lamivudine—Pruritus—Doxorubicin—muscle cancer	7.21e-05	0.000663	CcSEcCtD
Lamivudine—Nausea—Methotrexate—muscle cancer	6.99e-05	0.000643	CcSEcCtD
Lamivudine—Diarrhoea—Doxorubicin—muscle cancer	6.97e-05	0.000642	CcSEcCtD
Lamivudine—ABCC3—Metabolism—FH—muscle cancer	6.85e-05	0.00175	CbGpPWpGaD
Lamivudine—ABCC1—Metabolism of lipids and lipoproteins—MED12—muscle cancer	6.81e-05	0.00174	CbGpPWpGaD
Lamivudine—Dizziness—Doxorubicin—muscle cancer	6.74e-05	0.00062	CcSEcCtD
Lamivudine—DCK—Metabolism—MED12—muscle cancer	6.67e-05	0.00171	CbGpPWpGaD
Lamivudine—Vomiting—Doxorubicin—muscle cancer	6.48e-05	0.000596	CcSEcCtD
Lamivudine—Rash—Doxorubicin—muscle cancer	6.43e-05	0.000591	CcSEcCtD
Lamivudine—Dermatitis—Doxorubicin—muscle cancer	6.42e-05	0.000591	CcSEcCtD
Lamivudine—Headache—Doxorubicin—muscle cancer	6.39e-05	0.000587	CcSEcCtD
Lamivudine—DCK—Metabolism—ENO2—muscle cancer	6.08e-05	0.00156	CbGpPWpGaD
Lamivudine—Nausea—Doxorubicin—muscle cancer	6.06e-05	0.000557	CcSEcCtD
Lamivudine—PGK1—Disease—MDM2—muscle cancer	5.94e-05	0.00152	CbGpPWpGaD
Lamivudine—NT5C—Metabolism—PTGS2—muscle cancer	5.88e-05	0.0015	CbGpPWpGaD
Lamivudine—PCYT2—Metabolism—PTGS2—muscle cancer	5.88e-05	0.0015	CbGpPWpGaD
Lamivudine—CMPK1—Metabolism—PTGS2—muscle cancer	5.88e-05	0.0015	CbGpPWpGaD
Lamivudine—ABCB1—Integrated Pancreatic Cancer Pathway—BUB1B—muscle cancer	5.77e-05	0.00148	CbGpPWpGaD
Lamivudine—PGK1—Disease—PTGS2—muscle cancer	5.72e-05	0.00146	CbGpPWpGaD
Lamivudine—ABCC1—Metabolism—FH—muscle cancer	5.37e-05	0.00137	CbGpPWpGaD
Lamivudine—ABCC4—Hemostasis—IGF2—muscle cancer	5.36e-05	0.00137	CbGpPWpGaD
Lamivudine—PGK1—Metabolism—PTGS2—muscle cancer	4.79e-05	0.00123	CbGpPWpGaD
Lamivudine—ABCG2—Metabolism—FH—muscle cancer	4.72e-05	0.00121	CbGpPWpGaD
Lamivudine—SLC22A2—Metabolism—FH—muscle cancer	4.68e-05	0.0012	CbGpPWpGaD
Lamivudine—ABCB1—HIF-1-alpha transcription factor network—VEGFA—muscle cancer	4.54e-05	0.00116	CbGpPWpGaD
Lamivudine—SLC22A2—Transmission across Chemical Synapses—MDM2—muscle cancer	4.51e-05	0.00115	CbGpPWpGaD
Lamivudine—PCYT1A—Metabolism—PTGS2—muscle cancer	4.46e-05	0.00114	CbGpPWpGaD
Lamivudine—SLC22A1—Metabolism—FH—muscle cancer	4.36e-05	0.00111	CbGpPWpGaD
Lamivudine—ABCC4—Platelet activation, signaling and aggregation—VEGFA—muscle cancer	4.36e-05	0.00111	CbGpPWpGaD
Lamivudine—SLC22A3—Metabolism—MED12—muscle cancer	4.21e-05	0.00108	CbGpPWpGaD
Lamivudine—SLC22A1—Transmission across Chemical Synapses—MDM2—muscle cancer	4.2e-05	0.00108	CbGpPWpGaD
Lamivudine—NME2—Metabolism—PTGS2—muscle cancer	4.08e-05	0.00104	CbGpPWpGaD
Lamivudine—ABCB1—Allograft Rejection—VEGFA—muscle cancer	3.93e-05	0.00101	CbGpPWpGaD
Lamivudine—ABCC3—Metabolism—MED12—muscle cancer	3.87e-05	0.00099	CbGpPWpGaD
Lamivudine—SLC22A3—Metabolism—ENO2—muscle cancer	3.84e-05	0.000982	CbGpPWpGaD
Lamivudine—ABCC3—Metabolism—ENO2—muscle cancer	3.53e-05	0.000903	CbGpPWpGaD
Lamivudine—SLC22A2—Neuronal System—MDM2—muscle cancer	3.46e-05	0.000884	CbGpPWpGaD
Lamivudine—ABCC1—Disease—ENO2—muscle cancer	3.3e-05	0.000845	CbGpPWpGaD
Lamivudine—SLC22A1—Neuronal System—MDM2—muscle cancer	3.22e-05	0.000824	CbGpPWpGaD
Lamivudine—NME1—Metabolism—PTGS2—muscle cancer	3.09e-05	0.00079	CbGpPWpGaD
Lamivudine—ABCC1—Metabolism—MED12—muscle cancer	3.03e-05	0.000776	CbGpPWpGaD
Lamivudine—ABCC1—Disease—HMGA1—muscle cancer	3e-05	0.000768	CbGpPWpGaD
Lamivudine—ABCC1—Metabolism—ENO2—muscle cancer	2.77e-05	0.000708	CbGpPWpGaD
Lamivudine—ABCC3—Metabolism of lipids and lipoproteins—PTGS2—muscle cancer	2.76e-05	0.000706	CbGpPWpGaD
Lamivudine—ABCC1—Disease—FOXO4—muscle cancer	2.69e-05	0.000689	CbGpPWpGaD
Lamivudine—ABCG2—Metabolism—MED12—muscle cancer	2.67e-05	0.000683	CbGpPWpGaD
Lamivudine—SLC22A2—Metabolism—MED12—muscle cancer	2.64e-05	0.000676	CbGpPWpGaD
Lamivudine—ABCB1—Integrated Pancreatic Cancer Pathway—MDM2—muscle cancer	2.56e-05	0.000654	CbGpPWpGaD
Lamivudine—ABCB1—Metabolism—FH—muscle cancer	2.55e-05	0.000653	CbGpPWpGaD
Lamivudine—ABCB1—Integrated Pancreatic Cancer Pathway—PTGS2—muscle cancer	2.46e-05	0.00063	CbGpPWpGaD
Lamivudine—SLC22A1—Metabolism—MED12—muscle cancer	2.46e-05	0.00063	CbGpPWpGaD
Lamivudine—ABCG2—Metabolism—ENO2—muscle cancer	2.43e-05	0.000623	CbGpPWpGaD
Lamivudine—SLC22A2—Metabolism—ENO2—muscle cancer	2.41e-05	0.000616	CbGpPWpGaD
Lamivudine—ABCC4—Hemostasis—VEGFA—muscle cancer	2.25e-05	0.000575	CbGpPWpGaD
Lamivudine—SLC22A1—Metabolism—ENO2—muscle cancer	2.25e-05	0.000574	CbGpPWpGaD
Lamivudine—ABCC1—Metabolism of lipids and lipoproteins—PTGS2—muscle cancer	2.16e-05	0.000553	CbGpPWpGaD
Lamivudine—DCK—Metabolism—PTGS2—muscle cancer	2.12e-05	0.000542	CbGpPWpGaD
Lamivudine—ABCC1—Disease—FOXO1—muscle cancer	1.99e-05	0.000509	CbGpPWpGaD
Lamivudine—ABCB1—Integrated Pancreatic Cancer Pathway—VEGFA—muscle cancer	1.94e-05	0.000497	CbGpPWpGaD
Lamivudine—ABCC4—Hemostasis—TP53—muscle cancer	1.7e-05	0.000434	CbGpPWpGaD
Lamivudine—ABCC1—Disease—KIT—muscle cancer	1.52e-05	0.000388	CbGpPWpGaD
Lamivudine—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—muscle cancer	1.47e-05	0.000375	CbGpPWpGaD
Lamivudine—ABCB1—Metabolism—MED12—muscle cancer	1.44e-05	0.000369	CbGpPWpGaD
Lamivudine—SLC22A3—Metabolism—PTGS2—muscle cancer	1.34e-05	0.000342	CbGpPWpGaD
Lamivudine—ABCB1—Metabolism—ENO2—muscle cancer	1.32e-05	0.000337	CbGpPWpGaD
Lamivudine—ABCC3—Metabolism—PTGS2—muscle cancer	1.23e-05	0.000315	CbGpPWpGaD
Lamivudine—ABCC1—Disease—MDM2—muscle cancer	1.19e-05	0.000305	CbGpPWpGaD
Lamivudine—ABCC1—Disease—PTGS2—muscle cancer	1.15e-05	0.000294	CbGpPWpGaD
Lamivudine—ABCC1—Metabolism—PTGS2—muscle cancer	9.63e-06	0.000246	CbGpPWpGaD
Lamivudine—ABCG2—Metabolism—PTGS2—muscle cancer	8.48e-06	0.000217	CbGpPWpGaD
Lamivudine—SLC22A2—Metabolism—PTGS2—muscle cancer	8.39e-06	0.000215	CbGpPWpGaD
Lamivudine—SLC22A1—Metabolism—PTGS2—muscle cancer	7.82e-06	0.0002	CbGpPWpGaD
Lamivudine—ABCB1—Metabolism—PTGS2—muscle cancer	4.58e-06	0.000117	CbGpPWpGaD
